WSJ : Third Avenue Weighs Sale of High-Yield Fund That Halted Redemptions in Dec

Third Avenue Weighs Sale of High-Yield Fund That Halted Redemptions in December

New York firm taps Houlihan Lokey to shop Focused Credit Fund

Third Avenue Management LLC is weighing a sale of its high-yield mutual fund, whose meltdown spooked investors and fueled a selloff in the junk-bond market late last year.

The New York firm tapped investment bank Houlihan Lokey Inc. to shop its Third Avenue Focused Credit Fund, which had assets of $592 million as of June 30, according to people familiar with the matter. Proceeds from a sale would go to the fund’s investors, who lost the ability to withdraw money when the firm halted redemptions in December.

The firm also is exploring a deal under which another asset manager would team with it in managing a chunk of the fund’s assets, which could repay some of the money owed investors while offering a buyer control over some of the portfolio, the people said. Any deal would be subject to approval by the fund’s investors and the Securities and Exchange Commission, they added.

A sale could help remedy a painful saga for investors in the fund, which offered the freedom to cash out at any time alongside the potential rewards of betting on risky companies’ debt. That combination proved untenable late last year, when heavy selling in junk bonds fueled a rush to the exits among investors.

To avoid a fire sale of the fund’s assets, Third Avenue locked up investor money. The move, nearly unheard of for a mutual fund, shocked the market and left a black mark on Third Avenue, an investment firm founded by renowned value investor Marty Whitman.
The meltdown led to the dismissal of longtime Third Avenue executive David Barse, who was escorted out of the building after the firm’s management committee rejected his plan to sell the fund’s assets to private-equity firm Fortress Investment Group LLC, The Wall Street Journal reported.


The episode sparked broader fears about the health of the market for risky debt. Some banks and assets managers have argued that credit-market liquidity has deteriorated since the financial crisis due to new rules limiting banks’ traditional role facilitating trading in mutual funds, exchange-traded funds and similar products.

The Third Avenue incident prompted the SEC to conduct emergency examinations of about 80 mutual and exchange-traded funds that invest in high-yield bonds, bank loans and other risky, hard-to-sell assets. The regulator concluded that other funds didn’t pose the same risks as the Third Avenue fund, the Journal reported.

Junk bonds have since rebounded, with the Barclays U.S. corporate high-yield index returning 9% this year through June. The Third Avenue credit fund, which contains harder-to-trade assets than those held by many of its peers, is down 0.8% during the same period, according to its most recent fact sheet.

Since it halted redemptions, the fund has been selling assets and has made two distributions to investors. It is possible that by selling a chunk or all of the fund at once, it could appeal to buyers looking to acquire large positions at once or who want to get into the mutual fund business.

It is unclear what price the fund might fetch. The portfolio contains about $100 million in cash and a mix of public and private debt and equity investments, some of which are closely held and rarely or never trade publicly, according to people familiar with the fund. As a result, bidders might quibble with the firm’s valuation of the assets.

The fund has attracted interest from asset managers that traffic in high-yield and distressed debt, the people said. As part of a deal, the fund’s existing portfolio managers could continue to oversee its assets, they added.

>>> Three banks opt out of Monte dei Paschi's proposed 5 bln euro cash call - source


  • 28-Jul-2016 18:05:57 - MORGAN STANLEY, UNICREDIT AND INTESA SANPAOLO REBUFF PROPOSAL TO GUARANTEE MONTE DEI PASCHI'S PROPOSED 5 BILLION EURO CASH CALL - SOURCE
  • 28-Jul-2016 18:05:58 - BANKING CONSORTIUM FOR CASH CALL EXPECTED TO INCLUDE MEDIOBANCA, JPMORGAN, CITIGROUP, BANK OF AMERICA, DEUTSCHE BANK AND CREDIT SUISSE, BUT MORE BANKS NEEDED - SOURCE

Three banks opt out of Monte dei Paschi's proposed 5 bln euro cash call - source - Reuters News

28-Jul-2016 18:08:16

By Pamela Barbaglia

LONDON, July 28 (Reuters) - Morgan Stanley MS.N and Italian lenders UniCredit CRDI.MI and Intesa SanPaolo ISP.MI have rebuffed a proposal by Italy's third-largest lender, Banca Monte dei Paschi di Siena BMPS.MI, to back its proposed 5 billion euro ($5.54 billion) cash call, a source familiar with the matter told Reuters.

The troubled lender is trying to pull together a banking consortium to guarantee its proposed capital increase in the next 24 hours so it has a plan in place by the time the results of the European bank stress tests are released on Friday evening. (Full Story)

Banking sources say the tests will show the bank has insufficient capital to withstand an economic downturn.

It has so far received interest from Citigroup C.N, Bank of America BAC.N, Deutsche Bank DBKGn.DE and Credit Suisse CSGN.S, the source said.

The consortium will also include Mediobanca MDBI.MI and JPMorgan JPM.N who are acting as global coordinators for the proposed capital hike, the source said.

Other banks including Societe Generale SOGN.PA, UBS UBSG.S and Nomura are currently being contacted in a bid to share the cost of the proposed transaction which is said to involve Monte dei Paschi issuing stock at between 0.5 and 0.6 percent of its tangible book value, the source said.

"As things stand now, the consortium is weak," the source said. "More banks need to come onboard."

Another source, who is close to the Tuscan lender, said Monte dei Paschi is expected to release the guidelines of its rescue plan on Friday and is confident of reaching a pre-agreement with a sufficient number of banks "in due time."

Monte dei Paschi, Mediobanca, JPMorgan, UniCredit and Intesa declined to comment. The other banks were not immediately available for comment.

WSJ : SABMiller-AB InBev: Don’t Bet on a Breakup

SABMiller-AB InBev: Don’t Bet on a Breakup
The world’s two largest brewers will probably still tie the knot

The beer has turned cloudy at the bottom of the bottle, but investors should drink up anyway.

When Anheuser-Busch InBev was offering £44 a share for SABMiller, shares in the U.K.-listed brewer traded above the bid price. Since ABI raised its offer to £45 Tuesday, the shares have fallen below £43.

This oddity follows an outburst of noise casting the long-awaited megamerger in doubt. Its most vocal opponent is Aberdeen Asset Management. It doesn’t like the two-tier structure, which involves a tax-efficient cash-and-unlisted-shares package for the largest two shareholders and a cash-only offer for the rest. For all the guff about governance, the real problem is that the Brexit vote devalued the pound, making the all-cash offer less attractive than the one that includes the unlisted shares.

But chances are the deal will still go through this year. And if that’s the case, there is a fairly low-risk 5% to be made by buying SAB shares now.

Aberdeen is the only investor that has publicly denounced the deal, and it owns just 1.17% of the company. Even if the two big shareholders are barred from voting on the cash-only component of the offer, as Aberdeen wants, it will hold less than 2% of the votes. That compares to a probable 25% threshold for overturning the merger. So it will need a lot of allies.


Activist hedge funds such as Elliott have also been pushing for a higher price. Tuesday’s £1 increase is underwhelming, but it is also explicitly final under U.K. takeover rules. Now activists have every interest in preserving the deal, without which brokerage Evercore estimates SABMiller’s share value at roughly £35. Elliott, which bought more SAB shares yesterday, is unlikely to second Aberdeen’s claim that it would be “more than happy” to remain a long-term shareholder.

On this occasion it makes sense to buy the doubt.

Bilanz.ch : Novartis CEO holds larger acquisitions possible

Novartis CEO holds larger acquisitions possible
For three years, the Novartis leadership formed by the pharmaceutical giants. But not everything is running smoothly. To further catch up to CEO Joe Jimenez can imagine even larger acquisitions.

The pharmaceutical giant Novartis can again imagine larger acquisitions. "A takeover worth more than five billion dollars, I do not rule out," said Novartis CEO Joe Jimenenz towards "balance", "but in this case must be immediately visible their strategic and financial logic."

Previously, management had primarily spoken of supplementary acquisitions worth up to five billion dollars. Facing possible targets Jimenez thinks less of the cancer business, although analysts Novartis a lag in the immune oncology certify .: "There are in addition to the immune oncology a number of other regions in which acquisitions are conceivable, such as immunology or even the generic business, "says Jimenez.

>>> Gapping up

Gapping up
In reaction to strong earnings/guidance
: PCMI +26%, GRPN +24.6%, OCN+19.8%, QTM +19.2%, ESI +12.7%, CRUS +12.5%, PEIX +11.6%, LOGI +11.3%,AXTI +9.3%, ARRS +8.8%, MKSI +8.3%, VNR +6.7%, LM +6%, ESV +5.8%, NICE+5.1%, BZH +4.2%, FB +3.9%, AEM +3.8%, (also updates on its 2016 exploration activities at the Amaruq project, the Barsele project, the Madrono prospect adjoining the Pinos Altos and Creston Mascota operations and the El Barqueno project ), MRVL +3.7%, BT +3.6%, TTMI +3.4%, SPB+3.4%, NTGR +3.3%, BHI +3.3%, BSX +3.3%, GPN +3.3%, NVCR +3.1%, MMSI+3%, CDE +2.9%, LMAT +2.9%, NGD +2.9%, WFT +2.8%, SXCP +2.6%, TCK+2.6%, RTN +2.5%, ALKS +2.4%, HOLX +2.2%, GPRO +2.2%, LLNW +2%, FOE+2%, (also ends review of strategic alternatives, adds $25 mln to repurchase program), BKCC +2%, O +2%, NVDQ +1.9%, HSON +1.9%, ABCO +1.8%, OSK+1.8%, CAB +1.5%, IART +1.4%, MUR +1.3%, SJW +1.3%, PXD +1.2%, HSY+1.2%, LRCX +1.1%

M&A news: N +18.4% (to be acquired by Oracle (ORCL) for $109/share in cash, or ~9.3 bln), ORCL +2%

Other news:
  • EVOK +30.2% ( Intracoastal Capital discloses 6.4% passive stake)
  • ALR +20% (late move lower on reports of DoJ subpoena)
  • HTCH +2.9% ( discloses receipt of letter from the Antitrust Division of the DOJ, which has opened an investigation relating to the sale of suspension assemblies for use in hard disk drives )
  • KITE +1.9% (enters into an exclusive, worldwide license with the NIH for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies)
  • BID +1.7% (ticking higher; Taikang Life Insurance discloses 13.52% active stake)
  • STB +1% (Student Transportation announces an amended and increased senior credit facility with a new five-year term, and refinancing of one of its subordinated convertible debentures)
Analyst comments:
  • HOLX +2.3% (upgraded to Buy from Hold at Evercore ISI)
  • SPKE +1.2% (upgraded to Buy from Neutral at Janney)